SEPN: Septerna Corp Average Forecast Price
Septerna Inc (SEPN) possesses colossal potential in creating small molecules via the Native GPCR platform to combat immune pathologies. This chart captures the asset's market valuation trend, with the current figure standing at 59.39. The company attracts leading biologists through stock options, minimizing talent attrition. Simultaneously, energy-saving technologies and air purification systems are being implemented to comply with environmental regulations.
Analytical breakdowns for Septerna Corp (SEPN)
- price and consensus price forecast:
- market capitalization information:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Septerna Inc|SEPN - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Septerna Pharma|SEPN - Company Aggregate Debts|Debts to Book Capitalization Septerna Corp|SEPN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Septerna|Quick Liquidity Indicator septerna.com
- earnings and valuation multiples indicators:
SEPN - Net Profit|Projected Future Earnings Septerna Inc|SEPN - Price to Earnings Ratio|Future Price to Earnings Multiple Septerna, Inc.|SEPN - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Septerna Corp|SEPN - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Septerna|SEPN - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months septerna.com|SEPN - Net earnings per share growth this year|Earnings growth forecast for next year Septerna Inc
General company analysis:SEPN septerna.com
Minimizing fundamental risks requires an analysis of the evolving expectations of the professional community. This metric aggregates expert price targets into a single time series, measuring the weighted average fair value of the asset. For Septerna Inc (SEPN), this confirms the value of retaining a staff of rare GPCR specialists. A stable aggregate consensus valuation reflects market confidence in the company's intellectual capital, while the upward trend of the curve signals the reliability of the business model.
Competitors of Septerna Inc
Analyst Median Target argenx.com|Analyst Consensus Forecast BNTX (BioNTech)|Abivax SA (ABVX) - Average Forecast Price|ADMA - Price Target Chart|Forecast Levels Chart PTGX|Immunovant, Inc. (IMVT) - Price Target Chart|Broker Consensus Forecast KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Pieris Pharmaceuticals, Inc. (PVLA) - Price Target Chart|Consensus Target Savara Inc|Consensus Target RIGL|Analyst Consensus Forecast AnaptysBio Inc.|Price Target Chart Astria Therapeutics (ATXS)|engene.com - Broker Consensus Forecast|Analyst Consensus Forecast RAPT (RAPT Therapeutics, Inc.)|Aerovate Therapeutics, Inc. (JBIO) - Average Forecast Price|ACRS - Price Target Chart|Analyst Median Target Kyverna Therapeutics, Inc KYTX|TLSA: Analyst Consensus Forecast|Average Forecast Price cabalettabio.com (CABA)|Price Target Chart Ventyx Biosciences, Inc.|Theratechnologies, Inc. - Forecast Levels Chart|Consensus Target AVTX (Avalo Therapeutics Inc.)|Analyst Forecast Prices ELDN|Analyst Consensus Forecast AGEN (Agenus)|climbbio.com (CLYM) - Average Forecast Price|ZURA - Price Target Chart|Fair Value Consensus ATYR (aTyr Pharma Inc)|adagene.com (ADAG) - Price Target Chart|Broker Consensus Forecast IMA|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|Analyst Consensus Forecast Equillium Bio|Consensus Target CNTB (Connect Biopharma)|IMUX (immunic-therapeutics.com) - Fair Value Consensus|Analyst Consensus Forecast ATRA (Atara Bio)|Analyst Median Target InflaRx NV (IFRX)|XFOR - Price Target Chart|ACET (Adicet Bio) - Broker Consensus Forecast|CELU: Analyst Consensus Forecast|Consensus Target INmune Bio Inc|Price Target Chart Barinthus Bio|Kezar Life Sciences Inc (KZR) - Analyst Median Target|Analyst Consensus Forecast SABS|AKTX - Average Forecast Price|Price Target Chart Enlivex Therapeutics Ltd. ENLV|QTTB (Q32 Bio Inc) - Forecast Levels Chart|GOVX - Price Target Chart|EDSA (Edesa Biotech Corp) - Broker Consensus Forecast|iBio, Inc. (IBIO) - Price Target Chart|Forecast Levels Chart CARM (Carisma Therapeutics Inc.)|XTLB (XTL Biopharmaceuticals Ltd.) - Analyst Consensus Forecast|BOLT: Fair Value Consensus|Analyst Consensus Forecast HCWB|Analyst Consensus Forecast aptevotherapeutics.com (APVO)|Price Target Chart AIM ImmunoTech AIM|Fair Value Consensus ADTX|GRI - Price Target Chart|XORTX Therapeutics Inc (XRTX) - Consensus Target|HIND: Analyst Consensus Forecast|Revelation Biosciences Corp (REVB) - Analyst Consensus Forecast|Consensus Target INDP|SCNI: Fair Value Consensus|Analyst Consensus Forecast CALI|Analyst Median Target affimed.com|Price Target Chart Allakos ALLK|HOOK - Consensus Target|IGMS - Price Target Chart|iteostherapeutics.com (ITOS) - Consensus Target|OCEA (Ocean Biomedical) - Consensus Target|TC BioPharm (Holdings) Plc (TCBP) - Analyst Consensus Forecast|Price Target Chart Third Harmonic Bio, Inc
